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Abstract
The hERG potassium channel is critical to normal repolarization of cardiac
action potentials (APs) and loss- and gain-of-function hERG mutations are
associated, respectively, with long and short QT syndromes, pathological con-
ditions that can lead to arrhythmias and sudden death. hERG current (IhERG)
exhibits uniquely fast inactivation involving conformational changes to the
channel pore. The S631A hERG pore mutation was originally engineered to
interrogate hERG channel inactivation, but has very recently been found in a
family with short QT syndrome (SQTS). Accordingly, this study characterized
the effects of the S631A mutation on IhERG profile during ventricular, atrial,
and Purkinje fiber (PF) AP waveforms, using patch clamp recording from
hERG expressing HEK 293 cells at 37°C. Under conventional voltage clamp,
the current–voltage (I–V) relation for IhERG exhibited a marked right-ward
shift in the region of negative slope at positive membrane potentials. Under
ventricular AP clamp, the S631A mutation resulted in augmented IhERG, which
also peaked much earlier during the AP plateau than did wild-type (WT)
IhERG. Instantaneous I–V relations showed a marked positive shift in peak
repolarizing current during the ventricular AP in the S631A setting, while the
instantaneous conductance-voltage relation showed an earlier and more sus-
tained rise in S631A compared to WT IhERG conductance during ventricular
repolarization. Experiments with atrial and PF APs in each case also showed
augmented and positively shifted IhERG in the S631A setting, indicating that
the S631A mutation is likely to accelerate repolarization in all three cardiac
regions. Ventricular AP clamp experiments showed retained effectiveness of
the class Ia antiarrhythmic drug quinidine (1 lmol/L) against S631A IhERG.
Quinidine is thus likely to be effective in reducing excessively fast repolariza-
tion in SQTS resulting from the S631A hERG mutation.
Introduction
The process of ventricular repolarization in the heart
involves the combined activities of a number of potas-
sium (K+) channels (Tamargo et al. 2004). Among these,
the rapid delayed rectifier K+ current, IKr, is of particular
note, due to its association with both congenital and
acquired arrhythmias (Modell and Lehmann 2006; San-
guinetti and Tristani-Firouzi 2006; Hancox et al. 2008;
Hancox and Stuart 2018). Channels mediating IKr are
encoded by human Ether-a-go-go Related Gene (hERG;
alternative nomenclature KCNH2 (Sanguinetti et al. 1995;
Trudeau et al. 1995)) and are characterized by a uniquely
rapid voltage-dependent inactivation process that limits
IKr/hERG current (IhERG) at positive membrane potentials
(Sanguinetti et al. 1995; Trudeau et al. 1995; Smith et al.
1996). As a result, IKr normally contributes little to repo-
larization early during the ventricular action potential
(AP), but its contribution increases progressively, peaking
just before the terminal repolarization phase of the AP,
which is mediated by inwardly rectifying K+ current, IK1
(Ibarra et al. 1991; Hancox et al. 1998a; Zhou et al. 1998;
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Mitcheson and Hancox 1999). Inactivation gating of
hERG channels is also important for some (typically high
affinity) hERG blocking drugs to interact optimally with
their binding site(s) on the hERG channel (Sanguinetti
and Tristani-Firouzi 2006; Hancox et al. 2008).
In 2000 a condition called Short QT Syndrome
(SQTS), involving abbreviated ventricular repolarization
and susceptibility to arrhythmia was first identified (Gus-
sak et al. 2000). hERG was the first gene implicated as
causing SQTS in 2004, when a missense mutation in the
S5-Pore linker region (N588K) of the hERG channel was
found in SQTS families (Brugada et al. 2004). This muta-
tion leads to a profound positive shift in the voltage
dependence of inactivation of IhERG, with the consequence
that little inactivation occurs over physiologically relevant
membrane potentials and the size and timing of IhERG/IKr
during ventricular APs is significantly altered (Cordeiro
et al. 2005; McPate et al. 2005). The changes in kinetics
of IhERG/IKr caused by this mutation result in AP and
rate-corrected QT (QTc) interval abbreviation and to
shortening of the effective refractory period, which in
turn lead to an increased susceptibility to re-entrant
arrhythmia (Adeniran et al. 2011). Since the N588K
hERG mutation was linked to the SQTS, a number of
other hERG mutations have been identified in SQTS
patients, though until very recently none were found that
have such a profound effect on the channel’s inactivation
process as does N588K (for a review see Hancox et al.
2018).
The S631A hERG mutation has long been used as an
experimental tool to explore the inactivation process of
hERG and the effect of inactivation removal on drug
binding. This serine residue is located in the outer mouth
of the channel and Schoenherr and Heinemann (1996)
mutated it to match the analogous (alanine) residue in
non-inactivating eag-encoded channels, with the conse-
quence that inactivation of the hERG channel was pro-
foundly attenuated (Schoenherr and Heinemann 1996). A
subsequent detailed characterization of S631A hERG
channels expressed in Xenopus oocytes reported a
>100 mV positive shift in half maximal inactivation (Zou
et al. 1998), while limited AP voltage clamp data from
this laboratory, using a modified ventricular AP com-
mand, showed a marked effect of the mutation on cur-
rent timing during the AP (Hancox et al. 1998b). The
S631A mutation was subsequently shown to affect differ-
entially the inhibitory actions on hERG of the Class III
antiarrhythmic drug dofetilide (which was greatly
affected) and the Class Ia antiarrhythmic drug quinidine
(which was little affected) by the loss of inactivation due
to the mutation (Lees-Miller et al. 2000). The mutation
has subsequently been used widely in the study of drug
binding.
Very recently, the S631A hERG mutation has been
reported to occur in an SQTS family for the first time
(Akdis et al. 2018). The mutation was found in a 6-year-
old girl who was screened after the sudden death of a
cousin. She, her father and sister were all reported to have
abbreviated QTc intervals (of 340 msec or less, with the
index patient <320 msec). The index patient was asymp-
tomatic until she experienced syncope a decade later and
was fitted with an implantable defibrillator (ICD). She,
her father and sister were found to possess the S631A
mutation, while an asymptomatic brother did not. There
was also a history of sudden death on the father’s side of
the family (Akdis et al. 2018). The index patient also
expressed an SCN10A variant, but her father did not and
her mother, who also had the SCN10A variant, did not
have a short QT interval (Akdis et al. 2018). No in vitro
characterization of S631A was conducted in that study,
but from what is already known, the mutation’s effects
on repolarization are likely to be profound. The AP volt-
age clamp technique has been used to good effect in char-
acterizing the effects of the N588K hERG mutation
(Brugada et al. 2004; Cordeiro et al. 2005; McPate et al.
2005, 2009), including use to compare the effects of the
mutation on IhERG during different configuration AP
waveforms from different cardiac regions (Cordeiro et al.
2005; McPate et al. 2009). The study that is the subject of
this report was undertaken: (i) to provide comparative
information on the effects of the S631A mutation on the
profile of IhERG during atrial, ventricular, and Purkinje
fiber APs; (ii) to establish effectiveness of quinidine on
S631A IhERG under ventricular AP voltage clamp.
Methods
Cell culture and hERG expression
Human embryonic kidney cells (HEK 293; European Col-
lection of Cell Cultures, Porton Down, UK) were used for
all experiments. These were cultured at 37°C in Dul-
becco’s minimum essential medium with Glutamax-1 and
supplemented with 50 lg mL1 gentamycin and 10%
fetal bovine serum (Gibco, Paisley, UK). As demonstrated
previously, the attenuation of inactivation caused by the
S631A mutation causes significantly larger IhERG in mam-
malian cell expression (Hancox et al. 1998b; McPate et al.
2008). Consequently, a reduced volume of the mutated
cDNA was transfected into the cells in this study to pre-
vent excessively large currents and ensure accurate record-
ings. Transient transfection of 1 lg WT or 0.5 lg S631A
hERG cDNA, as previously (Hancox et al. 1998b; McPate
et al. 2008; Melgari et al. 2015) was performed using
Lipofectamine 2000 as per the manufacturer’s instructions
(Invitrogen, Paisley, UK). 0.15 lg of CD8 expression
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plasmid (in pIRES, donated by Dr I Baro, University of
Nantes, France) was co-transfected to use as a marker of
expression, with successfully transfected cells being identi-
fied using Dynabeads (Invitrogen, Paisley, UK) as per-
formed previously (Zhang et al. 2011; Du et al., 2014).
Following transfection, cells were dissociated using tryp-
sin-EDTA (Sigma-Aldrich, Gillingham, UK) and plated
on to 13 mm glass coverslips in Petri dishes containing
the same medium as used above to enable electrophysio-
logical recordings.
Solutions for electrophysiological
recordings
Similar to previous studies (McPate et al. 2005, 2008,
2009; Zhang et al. 2011), normal Tyrode’s solution con-
taining (in mmol/L): 140 NaCl, 4 KCl, 2.5 CaCl2, 1
MgCl2, 10 Glucose, and 5 HEPES was titrated to pH of
7.45 with NaOH for superfusion over the cells in a
recording chamber at 37  1°C. Patch-pipettes, fire pol-
ished to 2–4 MΩ, were filled with dialysis solution con-
taining (in mol/L): 130 KCl, 1 MgCl2, 5 EGTA, 5
MgATP, and 10 HEPES, titrated to pH of 7.2 using KOH
(McPate et al. 2005, 2008, 2009; Zhang et al. 2011).
Quinidine powder (Quinidine gluconate salt; Sigma-
Aldrich, Gillingham, UK) was dissolved in Milli-Q water
to produce a 1 mmol/L stock solution, and this was sub-
sequently diluted to 1 lmol/L in normal Tyrode’s solu-
tion to be used for experimentation.
Experimental protocols and analysis
An Axopatch 200A amplifier (Axon Instruments, Foster
City, CA, USA) and a CV201 head-stage were used to
make whole-cell patch clamp recordings of membrane
currents. All data were recorded via a Digidata 1440A
interface (Molecular Devices, Sunnyvale, CA, USA) using
a bandwidth of 2 kHz and a digitization rate of 10 kHz.
At least 70% of the electrode series resistance could be
compensated. Excel 2016 (Microsoft, Redmond, WA),
Prism 7 (Graphpad Inc, La Jolla, CA, USA), Clampfit
10.2 (Axon Instruments) and Origin 2017 (OriginLab
Corporation, Northampton, MA, USA) were all used for
data analysis as appropriate.
The relevant voltage protocols used are detailed within
the Results section. The action potential waveforms used
in action potential voltage clamp (AP clamp) experiments
have been employed in previous studies (McPate et al.
2005, 2008, 2009; El Harchi et al. 2010; Milnes et al.
2010; Zhang et al. 2011), and the currents elicited by
these were corrected online for P/N leak subtraction using
an interspersed P/4 protocol (McPate et al. 2005, 2008,
2009; El Harchi et al. 2010; Zhang et al. 2011). Successive
APs were applied at a start-to-start interval of 1 sec (Fig-
ures 2–4) or 12 sec (Figure 5). Total charge carried dur-
ing ventricular AP in the presence or absence of
quinidine was determined by integrating currents using
Origin 2017.
Voltage-dependent activation was obtained from plots
of normalized IhERG tails against voltage (Fig. 1D) with a
fit to the data with a Boltzmann equation of the form:
I ¼ Imax=ð1þ expððV0:5  VmÞ=kÞÞ
where the half-maximal activation voltage (V0.5) was
obtained by normalizing IhERG tail current values (I), fol-
lowing differing voltage commands, to the maximal IhERG
tail value observed during the voltage protocol (Imax),
plotting the resulting values against corresponding com-
mand voltage (Vm) and k is the slope factor describing
IhERG activation.
Fractional block of IhERG by quinidine was calculated
by the following equation:
Fractional block ¼ 1 ðIhERG½Drug=IhERG½ControlÞ
where IhERG [Drug] and IhERG [Control] represent peak
repolarizing currents or total current integral as appropri-
ate; in the presence and absence of quinidine, respec-
tively.
As in recent work from our laboratory (Helliwell et al.
2018), we used to the recent cryo-EM open pore structure
of hERG [PDB: 5VA1] (Wang and MacKinnon 2017) to
show the structural context of the S631 residue. The
structural figure (Fig. 6) was made using Pymol version
1.4 (Schroedinger, LLC, New York, NY, USA).
‘n’ values in the Results text and Figure Legends and
that were used for statistics refer to numbers of individual
cells from which observations were made. All data are
presented as the mean  standard error of the mean
(SEM), and statistical comparison made using a Student’s
t-test or one- or two-way analysis of variance (ANOVA)
and subsequent Bonferroni post hoc test. P values of less
than 0.05 were considered significant.
Results
Effects of S631A mutation on IhERG under
conventional voltage clamp
In initial experiments, a conventional voltage clamp pro-
tocol (lower traces of Fig. 1A and B) was used to elicit
IhERG across a range of test potentials. For WT IhERG a
holding potential of 80 mV was followed by 2 sec test
pulses to voltages between 40 mV and +60 mV, with
subsequent repolarization to 40 mV and then a return
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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to the holding potential (McPate et al. 2005; Zhang et al.
2011). As previously for N588K IhERG, (McPate et al.
2005; Zhang et al. 2011) this protocol was modified to
include test voltages up to +100 mV in S631A-hERG
expressing cells in order to fully capture current rectifica-
tion and the region of negative slope in the current–volt-
age (I–V) relation, that was positively shifted along the
voltage axis. For the protocol used to study S631A IhERG,
successive commands were separated by 20 mV rather
than 10 mV increments, in order to increase the likeli-
hood of successful completion of the protocol at highly
positive voltages. For WT IhERG, current during the test
pulse increased up to 0 mV and then declined at more
positive voltages. Following test pulses to positive test
potentials, resurgent tail currents were evident. For S631A
IhERG, on the other hand, current increased progressively
with increasing test potential magnitude up to +40 mV,
at which point current started to decline. Additionally,
for S631A hERG the tail currents on repolarization to
40 mV were smaller than IhERG during the test pulse,
across the entire range of voltages examined. Figure 1C
shows the mean I–V relations for IhERG (normalized to
current at +0 mV for the two expression conditions
(McPate et al. 2005)), showing that the region of negative
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Figure 1. Current–voltage (I–V) relationship for WT and S631A hERG. (A, B) Representative current traces for WT (A) and S631A (B) hERG
channels elicited by the protocols shown below. WT recordings were made using 10 mV voltage step increments between 40 mV and
+60 mV, whereas S631A recordings used 20 mV increments between 40 mV and +100 mV in order to fully encapsulate the shift in current
rectification. Selected traces are shown for clarity. (C) Mean I–V relations for end pulse WT (n = 7) and S631A (n = 5) IhERG, normalized to
current at 0 mV. (D) Mean normalized tail current I–V relations for the same WT (n = 7) and S631A (n = 5) experiments shown in C. Currents
were normalized to the peak current recorded during the protocol for each cell.
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slope in the I–V relation was shifted to more positive
potentials for S631A. Figure 1D shows normalized I–V
plots for WT and S631A IhERG tails, fitted with a Boltz-
mann equation to establish the voltage dependence of
activation. The half maximal voltage of activation was not
significantly different between the WT (16.8  3.0 mV;
n = 7) and S631A IhERG (14.4  1.8 mV; n = 5;
P > 0.05), and no change was seen in the slope (k) of the
fitted activation relation (8.0  1.5 mV for WT vs.
5.3  1.0 mV for S631A; P > 0.05). These comparative
properties of WT and S631A IhERG are similar to those
previously reported (e.g., (Schoenherr and Heinemann
1996; Zou et al. 1998; Hancox et al. 1998b; McPate et al.
2008). Positively shifted IhERG inactivation has previously
been well documented for the S631A mutation (e.g.,
Schoenherr and Heinemann 1996; Zou et al. 1998;
McPate et al. 2008) and under the same measurement
conditions as this study, previous work from this labora-
tory reported half maximal inactivation voltage for S631A
IhERG to be positively shifted by ~+88.5 mV (from
58.5 mV to + 30 mV; (McPate et al. 2008). As this volt-
age shift was recorded under similar measurement condi-
tions to those used for this study, we did not repeat that
experiment.
Effects of S631A mutation on IhERG elicited
by ventricular AP voltage clamp
Figure 2A shows representative traces of WT and S631A
IhERG recorded under ventricular AP clamp. As expected
(Hancox et al. 1998a; Zhou et al. 1998; Lu et al. 2001;
McPate et al. 2005), there was relatively little WT IhERG
early during the imposed AP command, but this increased
progressively throughout the AP plateau, peaking just
before the steep terminal repolarization phase of the AP
(Fig. 2Ai). The profile of S631A IhERG differed, being larger,
rising and peaking earlier during the AP plateau than for
the WT channel, which gave rise to an inverted U-shaped
current profile (Fig. 2Aii cf (Hancox et al. 1998b; McPate
et al. 2005)). Figure 2Bi and Bii show the instantaneous I–
V plots for WT and S631A IhERG during AP repolarization
(direction of repolarization indicated by the arrows on the
plots shown). For 6 cells, WT IhERG was maximal at
32.2  2.3 mV, whereas in 7 cells S631A IhERG was maxi-
mal at +21.5  2.6 mV (P < 0.0001 vs. WT). Thus, the
S631A mutation significantly shifted the timing of IhERG to
peak earlier during the ventricular AP waveform. Fig-
ure 2Ci and Cii show the instantaneous G–V plots for WT
and S631A IhERG, which take into account the instanta-
neous changes in driving force at each potentials as AP
repolarization proceeds (Hancox et al. 1998a; Lu et al.
2001; McPate et al. 2005, 2009). In the WT condition, the
instantaneous G–V relation increased progressively until
relatively late during the ventricular AP command. In con-
trast, for S631A hERG the G–V relation rose much earlier
during the AP plateau, reaching a maximum between ~0
and 30 mV and then progressively declining as the action
potential progressed. Thus, S631A hERG contributed sub-
stantial outward conductance, earlier during the AP and
over a larger voltage range than did WT hERG.
Effects of S631A mutation on IhERG during
atrial and Purkinje fiber APs
Figure 3 shows the results of AP clamp measurements of
WT and S631A IhERG during atrial (Fig. 3A and B) and
Purkinje fiber (PF) (Fig. 3C and D) AP waveforms. Due
to the different profile of the atrial from the ventricular
AP and, in particular, to a less positive plateau phase of
the atrial AP, the profile of WT IhERG during the AP dif-
fered from that in Figure 2, with a more modest increase
in IhERG throughout the repolarization phase and a rela-
tively flat peak between 20 and 40 mV (Fig. 3Ai and
Bi). The mean voltage at which WT IhERG peaked during
atrial AP repolarization was 25.7  3.0 mV (n = 6).
S631A IhERG was increased in magnitude and slightly pos-
itive shifted compared to the WT channel (Fig. 3Aii and
Bii), with peak current during repolarization occurring at
13.8  0.7 mV (n = 6; P < 0.01). The Purkinje fiber
(PF) AP used was intermediate between the atrial and
ventricular APs in terms of plateau and the profile of WT
IhERG was more similar to that during the ventricular than
during the atrial AP command (Fig. 3Ci and Di). Similar
to the ventricular AP command, WT IhERG peaked at
38.1  2.0 mV (n = 6). S631A IhERG was again aug-
mented compared to WT IhERG and the voltage at which
maximal IhERG occurred was positively shifted to
3.9  1.8 mV (n = 6; P < 0.0001; Fig. 3Cii and Dii).
The summary bar charts in Figure 4 show the magni-
tude of maximal IhERG (normalized to cell capacitance
and expressed as current density) elicited by each of the
three waveforms for WT (Fig. 4A) and S631A IhERG
(Fig. 4B). As in a previous study of N588K hERG
(McPate et al. 2009), we have compared magnitudes of
peak repolarizing current density between the different
AP commands for each channel type. Thus, for WT IhERG,
the magnitude of peak repolarizing current during the
ventricular AP was ~7.3 fold that during the atrial AP
and ~2.9 fold that during the PF AP. For S631A IhERG the
magnitude of peak repolarizing current during the ven-
tricular AP was ~7.2 fold that during the atrial AP and
~2.8 fold that during the PF AP. The most notable com-
parison here is between ventricular and PF APs, as both
cell types contribute to overall repolarization profile of
the ventricles; our results indicate that the ratio between
peak repolarizing IhERG in ventricular versus PF APs was
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Figure 2. IhERG during ventricular AP clamp. (A) Representative traces of WT (from a total of n = 6) and S631A IhERG (from a total of n = 7) in
response to a ventricular AP (overlaid in gray). (B) Representative plots of the instantaneous I–V relations during repolarization phase of the
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Figure 3. IhERG during atrial and PF AP clamp. (A) Representative traces of WT (from a total of n = 6) and S631A (from a total of n = 6) IhERG
in response to an atrial AP (overlaid in gray). (B) Representative plots of the instantaneous I–V relations during the repolarization phase of the
atrial AP command waveform. From 5 msec after the AP upstroke peak, currents were normalized to the maximal current recorded during the
protocol. (C) Representative traces of WT (from a total of n = 6) and S631A (from a total of n = 6) IhERG in response to Purkinje fiber AP
(overlaid in gray). (D) Representative plots of the instantaneous I–V relations during the repolarization phase of a Purkinje fiber AP. From
5 msec after the AP upstroke peak, currents were normalized to the maximal current recorded during the protocol. In B and D the arrows
represent the direction of repolarization.
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similar for S631A and WT IhERG. Figure 4C illustrates
graphically the mean values for the voltages at which peak
repolarizing current occurred for WT and S631A IhERG
for each of the three AP command waveforms, thereby
demonstrating for each AP type the shift in the timing of
maximal current to earlier (corresponding to a more pos-
itive voltage) during AP repolarization for S631A IhERG.
Effect of 1 lmol/L quinidine under AP clamp
Prior experiments performed using conventional voltage
clamp have shown that the inhibitory action of quinidine
is comparatively little affected by attenuated inactivation
hERG mutants (Lees-Miller et al. 2000; Wolpert et al.
2005; McPate et al. 2008). In the final experiments of this
study we tested a partial IhERG blocking concentration of
quinidine under AP clamp. Figure 5Ai and Aii show rep-
resentative traces of IhERG elicited by a ventricular AP
command in control and following application of
1 lmol/L quinidine. IhERG magnitude was reduced by
quinidine for both channels. Figure 5Bi shows mean frac-
tional block of peak repolarizing current during the AP
by 1 lmol/L quinidine: for WT IhERG the mean block was
71.9  3.5% (n = 5), while for S631A hERG this was
57.1  5.1% (n = 6; P < 0.05). We also quantified inhibi-
tion by measuring the reduction in total charge (current
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fiber AP commands (n = 7, 6, and 6 cells, respectively). Significant differences at P < 0.01 and P < 0.0001 are signified by ** and ****,
respectively. Note that the statistical comparisons shown in A and B were made between the different AP waveforms for each of WT and
S631A hERG and not between the two constructs. (C) Plots of the mean voltage at which peak repolarizing IhERG occurred during each of the
3 AP waveforms for WT and S631A IhERG. For the ventricular AP waveform, WT n = 6 and S631A n = 7. For the atrial AP and PF waveforms,
both WT and S631A n = 6. Significant differences at P < 0.01 and P < 0.0001 are signified by ** and ****, respectively.
2018 | Vol. 6 | Iss. 17 | e13845
Page 8
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
S631A hERG in Short QT Syndrome A. Butler et al.
integral) carried by hERG throughout the AP and Fig-
ure 5Bii shows this information for WT and S631A IhERG
(mean fractional reductions of 74.0  2.4% and
63.0  6.2%, respectively; P > 0.05). Taken together,
these data indicate that peak IhERG block by quinidine
was only modestly reduced by the S631A mutation, while
the reduction in total charge carried by hERG during the
AP command by quinidine was statistically similar
between WT and S631A conditions.
Discussion
Historical context of the S631A hERG
mutation
The S631A hERG mutation is a notable example of an
ion channel mutation found to be of clinical significance
(Akdis et al. 2018) long after it had been made artificially
to probe ion channel structure-function. The S631 residue
is located in the outer pore of the hERG channel, outside
the selectivity filter (Fig. 6; (Wang and MacKinnon
2017)). In early work to establish the underlying basis of
IhERG inactivation, cytoplasmic N terminal deletion was
found not to eliminate inactivation, whereas mutation of
S631 to alanine (the homologous residue in EAG channels
that lack the rapid inactivation of hERG channels) largely
eliminated inactivation over physiologically relevant
membrane potentials (Schoenherr and Heinemann 1996;
Zou et al. 1998). Experiments utilizing Xenopus oocyte
expression showed voltage-dependent inactivation to be
positively shifted by +102 mV, whereas voltage-dependent
activation was unaltered by the mutation (Zou et al.
1998). Work from this laboratory using a rabbit modified
ventricular AP under AP clamp showed a substantially
modified IhERG profile during AP repolarization (Hancox
et al. 1998b). Using mammalian cell expression and
recording at physiological temperature we subsequently
observed little alteration to IhERG activation and a
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profound positive (~ +88 mV) shift in voltage-dependent
inactivation with S631A, effects that were similar to those
of the N588K SQT1 mutation in the same study (McPate
et al. 2008). On this basis, following the recent identifica-
tion of the S631A mutation in an SQTS family (Akdis
et al. 2018), we proposed that the clinical consequences
of the S631A mutation, and potential pharmacological
treatments, are likely to be similar to those of the spatially
distinct N588K mutation (the location of which is shown
in Figure 6 for comparison with S631) (Hancox and
Stuart 2018). The results in this study bear out these
predictions.
Ventricular consequences of S631A IhERG
profile under AP clamp
The AP clamp method enables current measurement dur-
ing dynamic, physiological waveforms and thus mem-
brane potential “history” influences the current(s) of
interest elicited under AP clamp (Hancox et al. 1998a;
Noble et al. 1998; McPate et al. 2009). The data with
human ventricular AP clamp in Figure 2 of this study
show both augmentation in IhERG magnitude due to the
S631A mutation and a positive shift in peak repolarizing
current, with instantaneous I–V and G–V relations similar
to those reported previously for the N588K mutation
(Cordeiro et al. 2005; McPate et al. 2005, 2009). While
S631A IhERG amplitude was significantly augmented dur-
ing the AP, direct comparison between WT and S631A
current amplitudes here is precluded by the necessity to
use less of the S631A hERG expression construct to avoid
excessively large currents under voltage clamp. However,
prior simulation data have shown that the kinetic changes
due to the N588K mutation are able to increase IKr
amplitude to ~5-fold that for the WT condition (Adeni-
ran et al. 2011), whereas myocyte data with the hERG
activator ICA-105574, which profoundly positive-shifts
IhERG/IKr inactivation, have shown even larger proportion-
ate increases in current amplitude (Gerlach et al. 2010).
Thus, attenuation of IhERG inactivation by S631A can be
expected to lead to profound augmentation of IhERG. At
the single channel level, the S631A mutation has also been
reported to increase ion translocation rate (Zou et al.
1998), which would be anticipated also to contribute to
increased macroscopic IhERG/IKr.
Similar to prior studies of N588K hERG (Brugada
et al. 2004; Cordeiro et al. 2005; McPate et al. 2005,
2009) we compared the properties of singly expressed
WT and S631A mutant channels under AP clamp, while
the index patient was heterozygous for the S631A muta-
tion. In this regard, it is notable that recent work using
concatenated hERG tetramers containing variable num-
bers of subunits with the S631A mutation has shown
that while the effect of S631A in terms of inactivation is
graded, it is not linearly so (Wu et al. 2014). Thus, in
comparison to a concatemer with four WT subunits,
IhERG inactivation V0.5 was shifted by +53, +56, +68, and
+77 mV with 1, 2, 3, and 4 S631A-containing subunits,
respectively (Wu et al. 2014). This indicates that
heterozygous S631A expression can produce >70% of
the inactivation impairment of homozygous expression
and the results shown here are therefore likely substan-
tially to be relevant to the clinical situation. Further-
more, the close similarity of effects under ventricular AP
clamp of the S631A and N588K mutations (Cordeiro
et al. 2005; McPate et al. 2005, 2009) means that SQTS
simulations that have been performed previously to
mimic the N588K mutation at cell and tissue levels
(Adeniran et al. 2011) are likely also to be relevant to
the S631A mutation. Incorporation of the kinetic
changes to IKr resulting from the N588K mutation into
ventricular cell and tissue models led to abbreviation of
ventricular AP duration and of effective refractory per-
iod and to augmentation of voltage heterogeneity in
localized regions of ventricular tissue, leading to
increased susceptibility to unidirectional conduction
block and re-entry (Adeniran et al. 2011). In 2D and 3D
simulations, the N588K mutation led to a reduced sub-
strate size necessary for re-entry and thereby facilitate
re-entrant spiral and scroll waves (Adeniran et al. 2011).
N588(K)
S631(A)
SF
Y652
F656
Figure 6. Location on hERG of the S631 residue. S631 and other
key residues discussed in the text are highlighted in the open
channel structure of a hERG construct obtained by cryo-electron
microscopy (PDB 5VA1; Wang and MacKinnon 2017). S631 lies
adjacent to the top of the K+ selectivity filter (SF; S624VGFG628).
N588 lies close to the top of the selectivity filter on a helical
segment of the extracellular turret. S6 helix pore residues Y652 and
F656 which are important for binding of quinidine to hERG are
indicated and this region of the K+ permeation pathway below the
selectivity filter is the likely binding site for quinidine. One of the
four hERG subunits is colored gray.
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The S631A mutation can be anticipated to produce sim-
ilar electrophysiological changes in the ventricular myo-
cardium, and these may account for instances of
arrhythmic syncope and sudden death in the affected
family (Akdis et al. 2018).
S631A IhERG during atrial and Purkinje fiber
APs
SQTS is characterized by atrial as well as ventricular
arrhythmias (Maury et al. 2008; Harrell et al. 2015; Han-
cox et al. 2018) and SQT1 patients with the N588K muta-
tion have been reported to exhibit atrial fibrillation
(Brugada et al. 2004; Hong et al. 2005). In atrial simula-
tions, incorporation of the N588K mutation led to abbre-
viation of the effective refractory period and reduction of
the wavelength for re-entry, facilitating induction of spiral
waves (Loewe et al. 2014). As yet, there is no clinical evi-
dence as to whether the S631A hERG mutation increases
susceptibility to atrial fibrillation or tachycardia; the only
clinical information currently available reports arrhythmic
syncope and familial instances of sudden death (Akdis
et al. 2018). The results of our atrial AP clamp experi-
ments are of relevance in this regard, however, as they
demonstrate increased IhERG during AP repolarization
with the S631A mutation. The lower AP plateau of the
atrial AP command resulted in less extensive IhERG activa-
tion and hence a smaller net current in both WT and
mutant conditions than the corresponding condition dur-
ing the ventricular AP command. However, there was a
clear shift in the timing of peak IhERG to earlier following
the AP peak, along with augmentation in current. This
can be predicted to shorten atrial APD and effective
refractory period and, thereby, to facilitate atrial re-entry
(Nof et al. 2010; Loewe et al. 2014). Clinical verification
of such changes would require electrophysiological mea-
surements of atrial refractoriness from individuals harbor-
ing the S631A mutation.
Our data also show a significant alteration in the IhERG
profile during the Purkinje fiber AP waveform, consistent
with accelerated repolarization in the PF system also. Dif-
ferences between PF and ventricular APs result in differ-
ent extents of IhERG activation and current magnitude and
this is evident in both WT and S631A conditions. The
extent of the difference was similar under S631A and WT
conditions indicating that, under the conditions of this
study at least, the S631A mutation did not exacerbate
ventricular–PF differences in current magnitude, though
the mutation differentially affected the timing of peak
current during the two waveforms (Fig. 4C). The possible
contribution to ventricular arrhythmogenesis (syncope/
sudden death; (Akdis et al. 2018)) of ventricular-PF dif-
ferences in effects of the S631A mutation are not known.
Prior simulations of ventricular arrhythmogenesis with
the N588K mutation showed that changes to the electro-
physiological properties of the ventricular myocardium
with that mutation sufficed to produce an arrhythmo-
genic substrate without incorporation into the model of a
PF network (Adeniran et al. 2011). However, incorpora-
tion of PFs in future simulations (for both the N588K
and S631A mutations) would be valuable, in order to
determine how changes to PF activity contribute to the
overall ventricular arrhythmogenic substrate.
Effectiveness of quinidine
While many SQTS patients, including the index patient
with the S631A mutation, have received implantable
defibrillators to protect from sudden death (Maury et al.
2008; Akdis et al. 2018; Hancox et al. 2018), adjunct
pharmacology is also desirable to offset abbreviated repo-
larization and decrease arrhythmia risk (Hancox et al.
2018). Prior studies using conventional voltage clamp
have already shown that, despite interacting with canoni-
cal drug binding aromatic residues on the S6 helices
(Y652 and F656 (Lees-Miller et al. 2000; Sanchez-Chapula
et al. 2003) the positions of which are shown in Fig. 6),
in comparison with Class III methanesulfonanilide agents,
quinidine is relatively insensitive to perturbation of the
hERG channel’s inactivation process (Lees-Miller et al.
2000; Wolpert et al. 2005; McPate et al. 2006, 2008; Per-
rin et al. 2008). Thus, under conventional voltage clamp,
the IC50 for S631A IhERG inhibition by quinidine has been
reported to be ~1.25-fold to 3.5-fold that of WT IhERG
(Lees-Miller et al. 2000; McPate et al. 2008). The present
data using 1 lmol/L quinidine under AP clamp are con-
sistent with this, showing only a modest decrease in the
extent of S631A channel inhibition compared to the WT
channel when effects on peak IhERG during repolarization
were assessed and no statistically significant decrease in
quinidine reduction of the IhERG integral during the ven-
tricular AP. The N588K SQT1 hERG mutation has previ-
ously been demonstrated to have quantitatively similar
effects on potency of quinidine inhibition of IhERG under
conventional voltage clamp (with IC50 values 3.5- to 5.8-
fold those for WT IhERG; (Wolpert et al. 2005; McPate
et al. 2008)) and (hydro)quinidine is effective in prolong-
ing the QT interval in that form of SQT1 (Wolpert et al.
2005; Giustetto et al. 2011; Villafane et al. 2013). Impor-
tantly, (hydro)quinidine has recently also been confirmed
to be associated with prevention of life-threatening
arrhythmic events in SQTS patients (Mazzanti et al.
2017). For the N558K mutation at least, simulation data
suggest that the beneficial actions of quinidine on effec-
tive refractory period result from both IhERG/IKr inhibition
and the drug’s Na channel inhibitory action (Whittaker
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et al. 2017). At present there are no patient data regard-
ing effectiveness of quinidine in S631A hERG linked
SQT1 (Akdis et al. 2018). However, the similarity
between the effects of the N588K and S631A mutations
on potency of IhERG inhibition by quinidine in a direct
comparison (McPate et al. 2008) and the known effec-
tiveness of the drug in N588K hERG linked SQT1
strongly suggest that quinidine is likely to be effective at
delaying repolarization in the setting of S631A-linked
SQT1. Issues with (hydro)quinidine availability in some
countries (Mazzanti et al. 2017) may be problematic for
its use, however. In relation to this, it is worth high-
lighting that conventional voltage clamp experiments
have shown that the Class Ia agent disopyramide also
retains effectiveness against the S631A mutation (Paul
et al. 2001; McPate et al. 2008) and so disopyramide
might provide a viable alternative where quinidine is
unavailable.
Conclusion
This study has demonstrated marked alterations in IhERG
profile during human atrial, ventricular, and Purkinje
fiber AP waveforms with the S631A SQT1 mutation,
which would be anticipated to accelerate AP repolariza-
tion and abbreviate refractoriness. Quinidine retains effec-
tiveness against S631A hERG under ventricular AP clamp
and this provides a rational basis for its deployment in
this form of the SQTS.
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